uterine cancers
DESCRIPTION
Uterine Cancers. A. Alobaid , MBBS, FRCS(C), FACOG Consultant, Gynecologic Oncology Assistant professor, KSU Medical Director, Women’s Specialized Hospital King Fahad Medical City. Introduction. It is the most common malignancy of the female genital tract - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/1.jpg)
Uterine Cancers
A. Alobaid, MBBS, FRCS(C), FACOGConsultant, Gynecologic OncologyAssistant professor, KSUMedical Director, Women’s Specialized HospitalKing Fahad Medical City
![Page 2: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/2.jpg)
Introduction
It is the most common malignancy of the female genital tract
2-3% of women will develop endometrial cancer during their lifetime
Endometrial cancer is a disease that occurs primarily in postmenopausal women
![Page 3: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/3.jpg)
Epidemiology
The median age of adenocarcinoma of the uterine corpus is 61 years
20-25% of the patients will be diagnosed before the menopause
![Page 4: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/4.jpg)
Risk Factors Nulliparity Late menopause Obesity Anovulatory cycles, polycystic ovary
syndrome Unopposed estrogen exposure Tamoxifen Diabetes mellitus, hypertension
![Page 5: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/5.jpg)
Risk Factors
Women who used oral contraceptives at some time, had a 0.5 relative-risk of developing endometrial cancer compared with women who had never used oral contraceptives
Cigarette smoking apparently decreases the risk for development of endometrial cancer
![Page 6: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/6.jpg)
Tamoxifen The relative risk of endometrial cancer in
women taking tamoxifen in the adjuvant setting was 2.2
Tamoxifen causes subepithelial stromal hypertrophy which cause the endometrial stripe to be thickened on sonography
Current consensus opinion recommends annual pap smears for women taking tamoxifen, and endometrial biopsy only for women with abnormal vaginal bleeding
![Page 7: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/7.jpg)
Endometrial Hyperplasia
It represents a spectrum of morphologic and biologic alterations of the endometrial glands and stroma, ranging from an exaggerated physiologic state to carcinoma in situ
It results from protracted estrogen stimulation in the absence of progestin influence
![Page 8: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/8.jpg)
Endometrial Hyperplasia
![Page 9: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/9.jpg)
Endometrial Hyperplasia
The risk of endometrial hyperplasia progressing to carcinoma is related to the presence and severity of cytologic atypia
Progestin therapy is very effective in reversing endometrial hyperplasia without atypia but is less effective for endometrial hyperplasia with atypia
![Page 10: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/10.jpg)
Symptoms of Endometrial Cancer
90% of women have vaginal bleeding or discharge as their only presenting complaint
Less than 5% of women diagnosed with endometrial cancer are asymptomatic
![Page 11: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/11.jpg)
Postmenopausal Bleeding
![Page 12: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/12.jpg)
Postmenopausal Bleeding
60-80% of patients with postmenopausal bleeding have endometrial atrophy
Only about 10% of the patients have endometrial cancer
The older the patient is, the greater the risk of cancer
![Page 13: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/13.jpg)
Diagnosis Office endometrial aspiration is the first
step in evaluating a patient with abnormal uterine bleeding
The diagnostic accuracy of office-based endometrial biopsy is 98%
A critical review of 33 reports of 13,598 D&Cs and 5851 office biopsies showed that D&C had a higher complication rate than office biopsy but that the adequacy of the specimens was comparable
![Page 14: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/14.jpg)
Diagnosis If the initial biopsy result is negative,
further evaluation is recommended in patients with persistent symptoms, due to the high risk (11%) of an existing lesion having been overlooked
Feldman S, gynecol Oncol, 1994;55:56-9
![Page 15: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/15.jpg)
Diagnosis
Endometrial thickness of less than 4mm as measured by ultrasonography is highly suggestive of endometrial atrophy (sensitivity 96-98%, specificity 36-68%, false negative rate 0.2%)
![Page 16: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/16.jpg)
Pathology There appear to be two different
pathogenetic types of endometrial cancer The most common type occur in younger
perimenopausal women with a history of exposure to unopposed estrogen
These estrogen-dependent tumors tend to be better differentiated and have a more favorable prognosis
The other type occur in older, thin women with no source of estrogen stimulation
![Page 17: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/17.jpg)
Pathology
![Page 18: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/18.jpg)
![Page 19: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/19.jpg)
![Page 20: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/20.jpg)
![Page 21: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/21.jpg)
Prognostic Factors
![Page 22: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/22.jpg)
Treatment
Exploratory lapratomy, peritoneal washing (cytology), total abdominal hysterectomy and bilateral salpingo-oopherectomy are the primary operative procedures for carcinoma of the endometrium
![Page 23: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/23.jpg)
Treatment
![Page 24: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/24.jpg)
Treatment
Patients with stage I grade 1 and 2 tumors without myometrial invasion (stages IA, G1, G2) have an excellent prognosis and require no postoperative therapy
Patients with stages IC or IA/IB G3 are given postoperative vaginal cuff irradiation
![Page 25: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/25.jpg)
Treatment Patients with stage II are treated similar
to patients with cervical cancer, the options are: Wertheim radical hysterectomy with BSO, bilateral pelvic lymphadenectomy and selective aortic node dissection,
extrafascial TAHBSO followed by adjuvant whole pelvis radiation therapy,or with whole-pelvis radiation therapy, followed by TAHBSO and selective para-aortic lymphadenectomy
![Page 26: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/26.jpg)
Treatment
Patients with stage III after a thorough surgical staging are treated with postoperative adjuvant pelvic radiation therapy
Patients with stage IV are usually most suitable for systemic hormonal therapy or chemotherapy and possible local radiation
![Page 27: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/27.jpg)
![Page 28: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/28.jpg)
Follow-up
Patients are followed up in the first two years every 3-4 months, thereafter the patients are followed every 6 months for the following three years
After 5 years of remission, the follow-up will be annual
![Page 29: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/29.jpg)
Recurrence In the early stage disease treated by
surgery only, recurrences are usually local/pelvic
Local recurrences are preferably managed by radiation, surgery, or a combination of the two
Patients with non-localized recurrences are treated with hormonal therapy or chemotherapy
![Page 30: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/30.jpg)
Sarcomas Sarcomas of the uterus are rare, and
carry a poor prognosis 2-6% of uterine cancers. The incidence appears to be changing,
increasing recently, part of this may be due to better recognition by pathologists.
Some of this increase, also, can be attributable to the greater use of pelvic radiation therapy.
![Page 31: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/31.jpg)
Classification
These tumors arise either from the endometrium: MMMT (carcinosarcoma) = 50% ESS = 8-10%
Or from the myometrium: LMS = 40%
![Page 32: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/32.jpg)
Sarcomas
MMT (Mixed Mullerian tumors): also they are called carcinosarcomas
Currently they are classifiedand and treated as poorly differentiated adenocarcinomas
Outcome is generally poor
![Page 33: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/33.jpg)
![Page 34: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/34.jpg)
Leiomyosarcomas (LMS) They arise from either the myomertrium
itself or the smooth muscle of the myometrial veins.
Most cases are diagnosed incidentally while performing surgery to fibroids
There is scant evidence in the literature to support the common teaching that rapid uterine enlargement heralds the onset of LMS.
![Page 35: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/35.jpg)
Leiomyosarcomas (LMS)
Treatment is surgical The spread of LMS is hematogenous,
so most recurrences are in distant sites
Chemotherapy is reserved for patients with advanced or recurrent disease
The 3-year progression-free survival for stage I and II patients is 21-31%
![Page 36: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/36.jpg)
![Page 37: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/37.jpg)
Endometrial Stromal Sarcomas LG ESS in premenopausal women. progress slowly with an indolent
clinical course. long term survival is the role. 5 years survival is 80-100%, but
about 37-60% will eventually recur after a very long time.
![Page 38: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/38.jpg)
HG ESSHG ESS
In postmenopausal women. More aggressive behavior,
frequent and early recurrence. 5 year survival is 25-55%, median
time to recurrence was 7 months
![Page 39: Uterine Cancers](https://reader036.vdocuments.net/reader036/viewer/2022062314/56814659550346895db375cb/html5/thumbnails/39.jpg)
Thank you